The randomized, double-blind, placebo-controlled study aims to enroll up to 40 patients with moderate-to-severe COVID-19 pneumonia in the U.S. —All six […]
WALTHAM, Mass., May 08, 2020 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) a global biopharmaceutical company pioneering targeted C3 therapies, […]